FIELD: biotechnology.
SUBSTANCE: obtained composition of the daclizumab preparation is suitable for subcutaneous administration and can be used for treatment of individuals suffering from multiple sclerosis.
EFFECT: claimed invention differs from the known analogues with other profiles of isoforms and N-linked glycosylation and shows a lower ADCC cytotoxicity.
8 cl, 38 tbl, 9 ex, 23 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOGLOBULIN COMPOSITIONS AND PRODUCTION PROCEDURE | 2004 |
|
RU2358763C2 |
| FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
| VERSIONS OF PERTUZUMAB AND THEIR ANALYTICAL CHARACTERISTICS | 2014 |
|
RU2737727C2 |
| SEPARATION AND PURIFICATION OF ANTIBODIES WITH APPLICATION OF PROTEIN A-BASED AFFINITY CHROMATOGRAPHY | 2009 |
|
RU2520838C2 |
| COMPOSITION OF PNEUMOCOCCAL CONJUGATE VACCINE | 2018 |
|
RU2789546C2 |
| IMPROVED PROTEIN PURIFICATION BY MEANS OF MODIFIED ELUATING OF PROTEIN A | 2010 |
|
RU2571929C2 |
| COMPOSITION CONTAINING ANTIBODY | 2010 |
|
RU2609658C2 |
| PROTEIN COMPOSITIONS AND METHODS FOR PREPARING THEM | 2008 |
|
RU2473360C2 |
| ISOLATION AND PURIFICATION OF ANTI-IL-13 ANTIBODIES USING PROTEIN A AFFINITY CHROMATOGRAPHY | 2010 |
|
RU2603055C2 |
| TRITERPENE COMPOSITIONS AND METHODS FOR THEIR APPLYING | 1999 |
|
RU2244547C2 |
